10.03.17
Noxilizer, Inc. and Sterigenics International LLC have signed a global agreement that will make Sterigenics an exclusive worldwide provider of nitrogen dioxide (NO2) contract sterilization services, as well as feasibility and research studies, to the pharmaceutical, biotech and medical device manufacturing industries.
NO2-based sterilization was first commercialized by Noxilizer in 2012 and offers advantages such as: ultra-low temperature (10°-30°C), minimal pressure requirements, no cytotoxic residuals, and faster cycle times (2-4 hours, including aeration). NO2 sterilization provides new opportunities for medical device innovation and has been shown to be particularly effective in the sterilization of prefilled syringes, drug-device combination products, and custom implants.
“We are very excited about our partnership with Sterigenics, as together we can rapidly expand NO2 sterilization capability for our customers,” said Lawrence Bruder, president and chief executive officer of Noxilizer. “Noxilizer’s customers will now have large-scale facilities to meet their needs for contract services, redundancy and increasing volumes.”
“Sterigenics is committed to providing our customers with efficient, state-of-the-art sterilization services using the processes best suited to their specific products," said Philip Macnabb, President of Sterigenics. "We regularly monitor new technologies and are excited to be able to add NO2 processing to our suite of offerings."
Noxilizer expects to have the first NO2 sterilization systems in place and operational in select Sterigenics’ facilities in the U.S. and Europe by the end of the year with additional installations to follow. As part of the agreement, Sterigenics will also offer nitrogen dioxide sterilization consulting services to its customers.
Customers will also have access to the integrated testing services available through Sterigenics International’s Nelson Laboratories business. “This unique combination of cutting edge sterilization technologies, expert consulting support, and full-service testing services will provide customers with unrivaled support in getting products to market quickly and reliably,” said Jeff Nelson, president of Nelson Labs.
NO2-based sterilization was first commercialized by Noxilizer in 2012 and offers advantages such as: ultra-low temperature (10°-30°C), minimal pressure requirements, no cytotoxic residuals, and faster cycle times (2-4 hours, including aeration). NO2 sterilization provides new opportunities for medical device innovation and has been shown to be particularly effective in the sterilization of prefilled syringes, drug-device combination products, and custom implants.
“We are very excited about our partnership with Sterigenics, as together we can rapidly expand NO2 sterilization capability for our customers,” said Lawrence Bruder, president and chief executive officer of Noxilizer. “Noxilizer’s customers will now have large-scale facilities to meet their needs for contract services, redundancy and increasing volumes.”
“Sterigenics is committed to providing our customers with efficient, state-of-the-art sterilization services using the processes best suited to their specific products," said Philip Macnabb, President of Sterigenics. "We regularly monitor new technologies and are excited to be able to add NO2 processing to our suite of offerings."
Noxilizer expects to have the first NO2 sterilization systems in place and operational in select Sterigenics’ facilities in the U.S. and Europe by the end of the year with additional installations to follow. As part of the agreement, Sterigenics will also offer nitrogen dioxide sterilization consulting services to its customers.
Customers will also have access to the integrated testing services available through Sterigenics International’s Nelson Laboratories business. “This unique combination of cutting edge sterilization technologies, expert consulting support, and full-service testing services will provide customers with unrivaled support in getting products to market quickly and reliably,” said Jeff Nelson, president of Nelson Labs.